Revolution Medicines, Inc. (RVMD) Q3 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call presents a mixed sentiment. The company's financial outlook shows a significant projected net loss, which is negative. However, there is strong product development with multiple trials underway, a positive partnership with Royalty Pharma, and potential for new market opportunities. The Q&A section highlights some uncertainties, such as unclear responses on trial event rates and efficacy thresholds, which dampen the overall sentiment. Given these mixed signals, a neutral stock price movement is expected over the next two weeks.
Key Financial Performance
Cash and Investments $1.93 billion as of Q3 2025, includes $250 million from Royalty Pharma in June 2025, with an additional $1.75 billion in future committed capital.
R&D Expenses $262.5 million in Q3 2025, up from $151.8 million in Q3 2024, a 72.9% increase. The rise is due to higher clinical trial-related expenses, manufacturing costs for 3 clinical stage programs, and increased personnel-related and stock-based compensation expenses.
G&A Expenses $52.8 million in Q3 2025, up from $24.0 million in Q3 2024, a 120% increase. The rise is attributed to higher personnel-related and stock-based compensation expenses, increased commercial preparation activities, and legal expenses.
Net Loss $305.2 million in Q3 2025, up from $156.3 million in Q3 2024, a 95.2% increase. The increase is primarily driven by higher operating expenses.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Daraxonrasib: Received three special designations from the FDA for pancreatic cancer: Breakthrough Therapy Status, Orphan Drug Designation, and Commissioner’s National Priority Voucher. Demonstrated strong clinical antitumor activity and durability in Phase I trials for second-line metastatic pancreatic cancer. Phase III trials (RASolute 302 and 303) are ongoing for first-line and second-line metastatic pancreatic cancer.
Zoldonrasib: Demonstrated compelling clinical profile with encouraging antitumor activity and favorable safety tolerability profile. Plans to initiate a combination registrational trial in first-line metastatic pancreatic cancer in 2026.
Elironrasib: Presented encouraging monotherapy data in heavily pretreated patients with G12C non-small cell lung cancer, showing a confirmed objective response rate of 42% and disease control rate of 79%.
RMC-5127: An oral tri-complex RAS(ON) G12V-selective inhibitor targeting KRAS G12V mutant cancer. First-in-human trial planned for Q1 2026.
Global Expansion: Expanded enrollment for trials in Europe and Japan for non-small cell lung cancer. Strengthened global commercialization capabilities with new appointments in the U.S. and European regions.
Financial Position: Ended Q3 2025 with $1.93 billion in cash and investments. Received $250 million from Royalty Pharma with $1.75 billion in future committed capital.
R&D and G&A Expenses: R&D expenses increased to $262.5 million in Q3 2025 due to clinical trial and manufacturing costs. G&A expenses rose to $52.8 million due to increased headcount and commercial preparation activities.
Strategic Collaborations: Collaborations with Tango Therapeutics and Summit Therapeutics to explore combinations of RAS(ON) inhibitors with other novel disease targets.
Advocacy Partnerships: Expanded partnerships with advocacy organizations to improve patient experience and develop patient-friendly clinical protocols.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Regulatory Risks: The company acknowledges that forward-looking statements are subject to many risks and uncertainties, which could materially impact actual results. This includes potential regulatory hurdles and delays in approvals for their investigational drugs.
Clinical Trial Risks: Ongoing Phase III trials and other clinical studies for daraxonrasib and other drugs are critical to the company's success. Delays in enrollment, adverse safety signals, or failure to meet endpoints could significantly impact their pipeline and commercialization plans.
Financial Risks: The company reported a significant increase in R&D and G&A expenses, leading to a higher net loss compared to the previous year. This financial strain could impact their ability to sustain long-term operations and development activities.
Operational Scaling Risks: The company is scaling its organization to support global commercialization and late-stage development. Challenges in hiring, operational inefficiencies, or delays in scaling could hinder their strategic objectives.
Market Competition: The company operates in a highly competitive oncology market. Competitors developing similar RAS-targeted therapies could limit their market share and revenue potential.
Supply Chain Risks: Manufacturing expenses for clinical-stage programs have increased, indicating potential supply chain challenges or inefficiencies that could disrupt drug production and delivery.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Daraxonrasib in Pancreatic Cancer: The Phase III RASolute 302 trial for second-line metastatic pancreatic cancer is nearing completion of enrollment, with data readout expected in 2026. Updated data for daraxonrasib in first-line metastatic pancreatic cancer, including durability, will be shared in the first half of 2026. The RASolute 303 trial for first-line metastatic pancreatic cancer will initiate this year, comparing daraxonrasib monotherapy and combination therapy to standard chemotherapy. The RASolute 304 trial for perioperative therapy in pancreatic cancer has been initiated, with site activation underway.
Zoldonrasib in Pancreatic Cancer: A registrational trial for zoldonrasib combination therapy in first-line metastatic pancreatic cancer is planned for the first half of 2026.
Non-Small Cell Lung Cancer (NSCLC) Program: The RASolve 301 trial for daraxonrasib in previously treated RAS-mutant NSCLC is enrolling patients globally. A registrational trial for daraxonrasib in first-line metastatic NSCLC, in combination with pembrolizumab and chemotherapy, is planned for 2026. Additional pivotal trials for zoldonrasib and elironrasib combinations in NSCLC are expected in 2026.
Elironrasib in NSCLC: Encouraging monotherapy data in heavily pretreated patients with G12C NSCLC were presented, with further development and combination trials planned.
RMC-5127 Development: The first-in-human trial for RMC-5127, targeting KRAS G12V mutant cancers, is on track to begin in Q1 2026.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:How are you thinking about the impact of receiving the Commissioner's National Priority Voucher on daraxonrasib timelines and your plans?
A:The voucher program aims to accelerate review timelines significantly, potentially reducing them to 1-2 months. The company is aggressively preparing for data readout and NDA submission and does not anticipate difficulties meeting the timeline under the CMDB process.
Q:Can you explain the decision to randomize against observation in the post-perioperative chemotherapy setting in the RASolute 304 trial?
A:The trial requires at least 4 months of perioperative chemotherapy as it is the standard of care. Patients are randomized to either no further treatment or 2 years of adjuvant therapy with daraxonrasib to build upon the modest success seen with chemotherapy in resectable pancreatic cancer. The potential to replace chemotherapy will be reassessed based on the adjuvant study results.
Q:How would you expect results from the Phase II RASolute 302 study to translate to the large global Phase III study?
A:The patient populations in Phase I and Phase III are fairly similar in baseline characteristics. The Phase III study is global, with predominant enrollment in the U.S. and representative enrollment in Europe and Japan. Historical consistency in Phase III trials gives confidence in replicating results.
Q:How are you tracking towards commercial readiness for daraxonrasib?
A:The company has a strong manufacturing organization and supply chain prepared to support product launch. The commercialization team is advancing launch readiness plans, including building capabilities in medical affairs, market access, marketing, and sales, and engaging with KOLs and advocacy organizations.
Q:How do you think about the efficacy of combination treatment relative to monotherapy in frontline metastatic PDAC?
A:Combination treatment and monotherapy test distinct hypotheses. Combination treatment may offer synergy and extend progression-free survival, while monotherapy introduces an additional line of therapy. Both approaches aim to provide survival benefits and options for patients.
Q:What additional information have you learned about the use of the National Priority Voucher since receiving it?
A:The company is in ongoing dialogue with the FDA but has no additional information to share about the voucher system's impact on NDA preparation.
Q:What considerations are there for selecting the doublet versus triplet in the zoldon combo Phase III in frontline PDAC?
A:The company is taking multiple approaches to treating PDAC and will provide more details when ready. The focus is on delivering impactful treatments for patients.
Q:Why is the zoldonrasib first-line trial only pursuing combinations?
A:Zoldonrasib is an ideal combination agent due to its safety and tolerability profile. The focus is on delivering impactful treatments and differentiating options for patients.
Q:How is the event rate in the RASolute 302 trial trending, and what is the disclosure strategy for interim results?
A:No comments were provided on the event rate or disclosure strategy for interim results.
Q:How are you thinking about the commercial opportunity in the European Union for daraxonrasib?
A:The company sees a meaningful opportunity in key European markets, including Germany and the EU4. They plan to bring a compelling value proposition and prioritize these markets along with the U.S. and Japan.
Q:What was the rationale behind starting the adjuvant study before the first-line study?
A:The adjuvant study is simpler with a single treatment arm and was ready to start earlier. However, it will have a longer readout timeline.
Q:Do you expect resistance mechanisms in non-small cell lung cancer to be similar to those in PDAC?
A:Resistance mechanisms in non-small cell lung cancer may differ from those in PDAC. The company is still analyzing data and cannot infer similarities at this stage.
Q:Does requiring 4 months of chemotherapy in the RASolute 304 study help select out borderline resectable patients?
A:No, the requirement standardizes treatment duration to make the patient population more uniform and comparable. It allows borderline resectable patients to receive adjuvant therapy if their perioperative therapy and surgery are successful.
Q:How are you thinking about the opportunity for zoldonrasib on top of chemo versus daraxonrasib plus chemo in RASolute 303?
A:Eligibility criteria for both studies are similar, with the main difference being that zoldonrasib targets all RAS mutations, while daraxonrasib targets KRAS G12D mutations.
Q:What key data points are you looking for in colorectal cancer before committing to earlier-line trials?
A:The company is exploring biologically rational combinations and aims to determine the most effective combinations for colorectal cancer, which is a complex disease.
Q:What is the efficacy threshold for daraxonrasib in first-line non-small cell lung cancer?
A:The company will compare single-arm trial data to standard of care but has not provided specific guidance on the efficacy threshold.
Q:How do acquired alterations post-daraxonrasib monotherapy impact durability in first-line treatment?
A:The company is exploring combinations with other mechanisms to address resistance and improve outcomes.
Q:Could an accelerated approval pathway be possible for first-line PDAC?
A:The company focuses on full approval strategies but is open to accelerated approval if the FDA deems it appropriate.
Q:Review of Unclear Management Responses
A:Management avoided providing direct answers to questions about the event rate in the RASolute 302 trial, disclosure strategy for interim results, and additional information about the National Priority Voucher's impact on NDA preparation. They also did not provide specific guidance on the efficacy threshold for daraxonrasib in first-line non-small cell lung cancer.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Chief Development
Development Officer
Dr Sandler
FOLFIRINOX gemcitabine
GX RAS
General Manager
GnP
III trial
Manager region
Phase III
President General
RAS group
Sandler Chief
Slide
appointment
care chemotherapy
chemotherapy antitumor
combination regimen
commercialization
control rate
cutoff progression
disease control
disease survival
elironrasib
gemcitabine capecitabine
line chemotherapy
line metastatic
metastatic PDAC
metastatic setting
monotherapy combination
monotherapy line
progression survival
rate disease
response rate
setting RASolute
site
strength
survival month
survival patient
track
tumor regression
RVMD Transcript
Revolution Medicines, Inc. (RVMD) Q1 2026 Earnings Call Transcript
Unknown5-7
The earnings call reveals mixed signals: a 15% revenue increase and a 10% improvement in net loss are positive, but there's a significant cash decrease and increased R&D expenses. Concerns about regulatory hurdles, competitive pressures, and economic uncertainties offset these positives. The absence of strategic discussions and unclear management responses in the Q&A further contribute to a neutral sentiment, suggesting limited immediate stock price movement.
Revolution Medicines, Inc. (RVMD) Presents at TD Cowen 46th Annual Health Care Conference Transcript
Neutral3-3
Revolution Medicines, Inc. (RVMD) Q4 2025 Earnings Call Transcript
Unknown2-25
The earnings call summary shows positive financial performance with a 25% revenue increase and a shift to net income from a loss, which is favorable. However, the lack of strategic updates and the presence of significant risks, such as regulatory hurdles and competitive pressures, balance the positives. The Q&A section did not provide additional insights to alter this view. Without information on market cap, we assume a neutral rating due to mixed signals from financial performance and strategic risks.
Revolution Medicines, Inc. (RVMD) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Neutral1-12
RVMD Slides
RVMD Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
